Search
Irbesartan
go.drugbank.com/drugs/DB01029ApprovedInvestigational[L7456,L7459] It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy. … [L7459] Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.[L7456,L7459] Irbesartan was granted FDA approval on 30 September 1997.[L7456,L7459]
Synonyms: 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-oneMixtures: IRBESARTAN/HCT AL 300/25, IRBESARTAN/HCT AL 300/25Arginine
go.drugbank.com/drugs/DB00125ApprovedInvestigationalNutraceuticalAn essential amino acid that is physiologically active in the L-form.
Synonyms: L-Arginin, L-(+)-ArginineMixtures: GNC PP L-Arginine L-Ornithine Tablet, Aminosyn II in DextroseMethionine
go.drugbank.com/drugs/DB00134ApprovedInvestigationalNutraceuticalA sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Synonyms: L-a-Amino-g-methylthiobutyric acid, L-MethioninMixtures: Clinimix 2.5% Travasol Aa Without Electrolytes In 10% Dextrose Injec, AA-VenBalsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approvedBalsam of Peru is a resin that comes from the tree Myroxylon balsamum pereirae. It is constituted by a mixture of substances from which the major components are benzyl cinnamate and [DB00676]. … [L2879] By Health Canada, the balsam of Peru is approved by the use of over-the-counter combination products and it is currently approved in veterinary products.
Mixtures: Arnica De LA Abuela, Stroke II SynergyCategories: Compounds used in a research, industrial, or household settingDinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalneuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. … Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse.
Linvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalFDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the
Respiratory Distress Syndrome
go.drugbank.com/conditions/DBCOND0027916Synonyms: Acute respiratory distress syndrome in adult or childCalcium
go.drugbank.com/drugs/DB01373ApprovedInvestigationalNutraceuticalCalcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. … Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day.
Mixtures: OSSOFORTIN A 70 MG+1200 MG/800 IU TEDAVİ PAKETİ, 4+24 ADET, Multi II IV Vi TabProducts: AAR OS N, Resto LDaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. … It is a botulinum toxin without accessory proteins purified from the bacterium _Clostridium botulinum_ type A,[L47840] the gram-positive anaerobic bacterium primarily present in soil.
Categories: Botulinum Toxins, Type AFondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalFondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. … angina (UA) and non-ST segment elevation myocardial infarction (NSTEMI); and in the management of ST segment elevation myocardial infarction (STEMI).
Categories: Factor Xa Inhibitors, Indirect factor Xa inhibitors